AI systems for scientific discovery
I build the reasoning layer of drug-discovery programs — from evidence to decision
What I do
Acting under uncertainty
There are no guarantees in science, nor in life, yet you still have to make choices. That's the challenge I build for - systems that help you make the best decisions possible given incomplete information. My work lives at the reasoning layer: turning complex, insufficient evidence into decision-grade substrate.
I'm a software engineer with 25 years of shipping, but philosophy is my first love. I trained in it alongside neuroscience, and I bring a systems-level, first-principles way of thinking to the design of scientific tools and programs.
Raising a child with a rare disease teaches you many things, not the least that if the answers don't exist yet, you have to find them yourself. So I'm building a decision-intelligence platform for running translational research programs — and proving it on a real one: I founded the CURE5 Foundation to accelerate therapies for CDKL5 Epilepsy, and I run its portfolio across AI-driven drug repurposing, cortical-organoid screening, iPSC development and small-molecule discovery, with Harvard, Boston Children's Hospital, BrainStorm Therapeutics, Unravel Biosciences and other labs.
Earlier I shipped FDA-cleared software for seizure detection and built real-time data systems now permanently installed at the 9/11 Memorial Museum. I also work with early-stage biotech and health-AI companies as a fractional CTO, helping them design their translational programs and architect the AI systems that will run them.
Selected work
- In development · 2025 → presentPrivate beta — walkthrough on request
A decision platform for drug discovery
Founder & builder
A decision-intelligence platform I'm building to run translational drug-discovery programs end to end — turning scattered biology (variants, mechanisms, screens, literature) into the small set of decisions that actually move a program forward. Multi-scale gene atlases and a structured knowledge layer, paired with AI agents that read the evidence and surface the next critical decision. In private use today, running a live rare-disease portfolio.
- 2023 → presentVisit →
CURE5 Foundation
Founder & operator
Running a translational research portfolio in AI-driven drug discovery, cortical-organoid screening, iPSC development and custom small-molecule therapeutics for CDKL5 Epilepsy. Partners: Harvard, Boston Children's Hospital, BrainStorm Therapeutics, Unravel Biosciences.
- 2025 → presentVisit →
Jimini Health
Senior AI Engineer
Full-stack engineering on a clinician-supervised AI behavioral-health platform ($25M-backed; advisory board includes DeepMind and Yale leaders) — building the patient-facing surface of an LLM product where model output meets clinical-safety review.
- PriorCase study →
FDA-cleared seizure detection software
Engineering lead
Clinical software for real-time seizure detection, developed through 510(k) clearance. Regulated, high-consequence shipping in a domain where accuracy directly affects patient care. Case study on request.
- Permanent installationWatch →
9/11 Memorial Museum — real-time visualization
Design & engineering, with Elevated Studio
A permanent installation at the National September 11 Memorial & Museum depicting the ongoing impact of 9/11 through real-time data and archival material.
- 2001 → presentVisit →
Elevated Studio
Founder
A boutique studio for scientific and medical visualization I founded in 2001. Selected work for the New York Times, Samsung, ConsenSys, ARoS Art Museum and the XQ Institute.
Working with me
A small number of engagements per year, with biotech and pharma teams that need someone who can architect the AI systems and translate between computation, wet-lab science and regulatory reality.
Typical engagements
- Fractional CTO for early-stage biotech and health-AI companies.
- Program design for translational discovery efforts — from data pipeline to wet-lab handoff.
- Technical due diligence for investors evaluating AI-in-biology theses.
Talks & media
Navigating Rare Disease Research: Data, Ethics & AI in Europe
Speaker — “Introduction to AI and drug repurposing.” EURORDIS Open Academy.
GATC 2026 — Genetic Agency Technology Conference
Speaker. Hosted by Dyno Therapeutics.
CURE5 Knowledge Engine
An AI tool that answers questions from the CDKL5 research literature, with citations.
CURE5 Foundation @ IEC2025
At the International League Against Epilepsy congress in Lisbon.
On AI & CDKL5 research
The CDKL5 in Color podcast, episode 35.